Mackenzie Financial
ALLO icon

Mackenzie Financial’s Allogene Therapeutics ALLO Stock Holding History

Mackenzie Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$893K Buy
+429,562
New +$943K ﹤0.01% 1210
2023
Q3 		– Sell
-53,192
Closed -$264K – 1469
2023
Q2 		$264K Buy
+53,192
New +$288K ﹤0.01% 1215

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Mackenzie Financial's ALLO Position: Q2 2026 in Review

Mackenzie Financial opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 429,562 shares worth $893K. The stake represents ﹤0.01% of the portfolio and ranks #1210 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in ALLO as recently as Q2 2023.

Mackenzie Financial first reported a position in ALLO in Q2 2023 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Mackenzie Financial held 429,562 shares of Allogene Therapeutics worth $893K as of Q2 2026.
  • Allogene Therapeutics was a new Mackenzie Financial position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #1210 holding.
  • Mackenzie Financial first reported a position in Allogene Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.